Description

Paclitaxel Concentrate for Infusions 6 mg/ml. 43.33 ml. (260 mg.)

Ingredients

Active ingredient: Paclitaxel. Inactive ingredients may include ethanol, polyoxyethylated castor oil, and citric acid.

Dosage

Dosage: The recommended dose of paclitaxel concentrate for infusions is determined by the patient’s body surface area and the specific condition being treated. It is administered intravenously by a healthcare professional.

Indications

Indications: Paclitaxel is indicated for the treatment of various cancers including breast cancer, ovarian cancer, and non-small cell lung cancer. It works by interfering with the growth and spread of cancer cells in the body.

Contraindications

Contraindications: This medication is contraindicated in patients with a history of hypersensitivity to paclitaxel or any of the ingredients in the formulation. It should not be used in pregnant women.

Directions

Administration: Paclitaxel concentrate for infusions should only be administered under the supervision of a healthcare provider experienced in the use of cancer chemotherapeutic agents. The infusion should be given slowly over 3 to 24 hours.

Scientific Evidence

Paclitaxel has been extensively studied in clinical trials and has shown significant efficacy in the treatment of various types of cancer. Research published in the Journal of Clinical Oncology demonstrated the effectiveness of paclitaxel in improving overall survival rates in patients with advanced ovarian cancer.

Additional Information

It is important to monitor patients receiving paclitaxel for infusion-related reactions, bone marrow suppression, and peripheral neuropathy. Close medical supervision is necessary during treatment to manage and mitigate potential side effects.

Paclitaxel exerts its pharmacological effects by disrupting microtubule function, leading to cell cycle arrest and apoptosis in cancer cells. This mechanism of action makes it a valuable component in the treatment of solid tumors.

Compared to other chemotherapeutic agents, paclitaxel has shown favorable efficacy and tolerability profiles in clinical studies. Its use in combination therapies has also been investigated, showing promising results in improving treatment outcomes for cancer patients.